Primary Mitral Regurgitation: without/with Heart Failure, Age 60 years

Ani C Anyanwu, MD

Professor and Vice-Chairman
Department of Cardiovascular Surgery
The Mount Sinai Medical Center
New York, USA





- 1. How is the Valve?
- 2. How is the patient feeling?
- 3. How is the heart?
- 4. How is the surgeon and what is the most likely operative result?
- 5. Is there reasonable expectation of net benefit of surgery?

- 1. How is the Valve?
 - Severity
 - Etiology
 - Repairability




Figure 4. Indications for Surgery for MR




Figure 4. Indications for Surgery for MR

Severity of Mitral Regurgitation (All the surgeon wants to know)

- SEVERE (intervene)
- MODERATE (observe)
- MILD (ignore)
- Or "DON'T KNOW" (seek further diagnostic data)

 Other distinctions, quantitative measurements and categorizations are unhelpful to the surgeon

The Pathophysiological Triad

Etiology



Lesions



Dysfunction

Reprinted from The Journal of Thoracic and Cardiovascular Surgery

Vol. 86, No. 3, pp. 323-337, September, 1983 (Printed in the U.S.A.) (Copyright © 1983, by The C.V. Mosby Company)

Volume 86. Number 3

September 1983

The Journal of THORACIC AND CARDIOVASCULAR SURGERY

I THORAC CARDIOVASC SURG 86:323-337, 1983

Honored Guest's Address

Cardiac valve surgery—the "French correction"

Alain Carpentier, M.D., Paris, France

Mr. President, I would like to begin by expressing my gratitude to the Association for the priviledge of presenting the Honored Guest Lecture at the Sixty-third Annual Meeting of The American Association for Thoracic Surgery. What surprises me the most in this meeting is my presence on this podium, since this honor is usually reserved for more senior and preeminent figures in thoracic surgery. I suppose that you wanted to distinguish a team rather than a man, so that I would

identification badge, I observed with great admiration and respect the famous people wearing a white printed badge and seated in a carefully delineated area of reserved seats! Permit me to tell you how proud I am to enter your prestigious circle.

Guests, you are seated outside this circle, but only temporarily! I address you specifically, since you represent the future of thoracic surgery and the future of this

Lesion based approach to mitral valve repair

Etiology

Lesions

Repair
Strategy



Etiology gives rise to lesions. Lesions determine the technique of repair – "one lesion, one technique"

Anyanwu AC and Adams DH; J Thorac Cardiovasc Surg 2008;36

Chordae tendineae Rupture

Etiology

Degenerative ('FED', Barlow's), endocarditis

Dysfunction

Leaflet prolapse – single or multiple segment. Type II

Treatment

Leaflet resection, chordal replacement



Ruptured chordae – A2 and P2



Chordae tendineae

Fusion, fibrosis, retraction, shortening

Etiology


Rheumatic, (congenital, iatrogenic, radiation, Barlow's)

Dysfunction

Leaflet restriction. Type IIIa

Treatment

Chordal fenestration, division or replacement, valve replacement



Thickened, fused chords to posterior leaflet



Leaflet Perforation

Etiology

Endocarditis, iatrogenic

Dysfunction

Normal leaflet motion –leak through perforation. Type I

Treatment

Direct suture, leaflet resection, patch closure



Posterior leaflet peforation



Leaflet Excess tissue - generalized

Etiology

Degenerative (Barlow's, Forme Fruste)

Dysfunction

Prolapse, billowing. Type II

Treatment

Resection



Excess tissue both in height and transversely



Leaflet

Thickening, retraction, fibrosis, calcification

Etiology

Rheumatic, post-surgical, radiation

Dysfunction

Restricted leaflet motion. Type IIIa, stenosis

Treatment

Leaflet 'shaving', leaflet decalcification, limited resection, valve replacement



Thickened non-pliable anterior leaflet with microcalcifications



- 1. How is the valve?
 - Is regurgitation severe
 - What is pathology and is it likely repairable?

PRACTICE GUIDELINE

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease



CLASS IIa

1. Mitral valve repair is reasonable in asymptomatic patients with chronic severe primary MR (stage C1) with preserved LV function (LVEF >60% and LVESD <40 mm) in whom the likelihood of a successful and durable repair without residual MR is greater than 95% with an expected mortality rate of less than 1% when performed at a Heart Valve Center of Excellence (39,86,415–419). (Level of Evidence: B)</p>

Is likelihood of durable repair greater than 95%?

- Degenerative yes (in centers of excellence)
- Annular dilatation yes
- Endocarditis depends on pathology and surgical skill available
- Rheumatic No (except in favorable pathology)
- Others depends on expertise and pathology

- 1. How is the Valve?
 - Not Severe watch. Severe go to question #2
- 2. How is the patient feeling?

Symptomatic Patients

- Surgery is recommended regardless of etiology of mitral regurgitation except
 - Very depressed LV function (EF <30%)
 - Very high patient risk

Surgery prolongs quality and quantity of survival

- 1. How much MR?
 - Not Severe watch. Severe go to question #2
- 2. How is the patient feeling?
 - Bad (dyspnea) Surgery. Good go to question #3

- 1. How much MR?
 - Not Severe watch. Severe go to question #2
- 2. How is the patient feeling?
 - Bad (dyspnea) Surgery. Good go to question #3
- 3. How is the heart?

Indications for surgery in the asymptomatic patient

Class I

- LVESD 40mm* (45mm ¶) or more
- LVEF 0.60 or less* ¶

Class Ila

- New onset Atrial Fibrillation*¶
- Rest PASP > 50 mmHg* ¶
- LVESD 40 mm or more if flail leaflet and repairable ¶
- Any asymptomatic patient if probability durable repair > 0.95 and mortality
 1% in center of excellence*

Class IIb

- Left atrial enlargement > 60ml/m² ¶
- Exercise PASP ≥ 60 mmHg

Provided low surgical risk and very high likelihood of repair

* AHA/ACC 2014 ¶ ESC 2012

LVESD – left ventricular end systolic dimension LVEF – left ventricular ejection fraction

Asymptomatic Patients

- Rationale for surgery
 - Prevent onset of symptoms
 - ? Prolong life
- Indications for surgery remain controversial
 - No good early discriminators of patients who will do poorly without surgery
 - Existing triggers for intervention reflect very advanced disease
 - No robust data demonstrating benefit of surgery in patients without triggers
 - Surgery is not risk free and can fail

Triggers for surgery in severe mitral valve regurgitation

Symptomatic patients – presence of symptoms alone indicates surgery

- Asymptomatic patients echocardiographic or hemodynamic triggers
 - Transthoracic Echocardiography
 - TEE
 - MRI
 - Exercise testing

What is new in 2014 Guidelines?

 Before excluding a patient from having a Class I indication for surgery

(and therefore opening up a choice of watchful waiting)

- Confirm asymptomatic status (exercise testing)
- Confirm the volume and function measurements from TTE are reliable
 - If doubt use TEE or CMR to validate LV volume and dimensions

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease



CLASS IIa

 Mitral valve repair is reasonable for asymptomatic patients with chronic severe nonrheumatic primary MR (stage C1) and preserved LV function (LVEF >60% and LVESD <40 mm) in whom there is a high likelihood of a successful and durable repair with 1) new onset of AF or 2) resting pulmonary hypertension (pulmonary artery systolic arterial pressure >50 mm Hg) (363,415,420-425). (Level of Evidence: B)

- 1. How much MR?
 - Not Severe watch. Severe go to question #2
- 2. How is the patient feeling?
 - Bad (dyspnea) Surgery. Good go to question #3
- 3. How is the heart?
 - LV dysfunction or dilatation Surgery
 - LA dilatation, AF, pulm HTN May consider Surgery
 - "Not" dilated or dysfunctional go to question # 4

- How much MR?
 - Not Severe watch. Severe go to question #2
- 2. How is the patient feeling?
 - Bad (dyspnea) Surgery. Good go to question #3
- з. How is the heart?
 - LV dysfunction or dilatation Surgery
 - LA dilatation, AF, pulm HTN May consider Surgery
 - "Not" dilated or dysfunctional go to question # 4
- 4. How is the surgeon and what is the most likely operative result?

PRACTICE GUIDELINE

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease



CLASS IIa

1. Mitral valve repair is reasonable in asymptomatic patients with chronic severe primary MR (stage C1) with preserved LV function (LVEF >60% and LVESD <40 mm) in whom the likelihood of a successful and durable repair without residual MR is greater than 95% with an expected mortality rate of less than 1% when performed at a Heart Valve Center of Excellence (39,86,415–419). (Level of Evidence: B)</p>

What is new?

Heart Valve Centers of Excellence

CLASS IIa

1. Mitral valve repair is reasonable in asymptomatic patients with chronic severe primary MR (stage C1) with preserved LV function (LVEF >60% and LVESD <40 mm) in whom the likelihood of a successful and durable repair without residual MR is greater than 95% with an expected mortality rate of less than 1% when performed at a Heart Valve Center of Excellence (39,86,415–419). (Level of Evidence: B)</p>

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease



development of Heart Valve Centers of Excellence. Heart Valve Centers of Excellence 1) are composed of experienced healthcare providers with expertise from multiple disciplines; 2) offer all available options for diagnosis and management, including complex valve repair, aortic surgery, and transcatheter therapies; 3) participate in regional or national outcome registries; 4) demonstrate adherence to national guidelines; 5) participate in continued evaluation and quality improvement processes to enhance patient outcomes; and 6) publicly report their available mortality and success rates. Decisions about intervention at the

What is new in 2014 guidelines?

- Class IIa recommendation for Early Surgery for any asymptomatic patient with severe MR, provided
 - Probability of repair is more than 95%
 - Probability of residual mitral regurgitation is less than 5%
 - Repair is likely to be durable
 - Operative mortality is below 1%
 - AND patient is in a "center of excellence"
- Otherwise operate only for a Class I trigger (onset of symptoms or LV dilatation or dysfunction)
- Note Class IIa triggers (pulmonary hypertension, atrial fibrillation)
 also mandate high reparability and durable repair in 2014 guidelines

- How much MR?
 - Not Severe watch. Severe go to question #2
- 2. How is the patient feeling?
 - Bad (dyspnea) Surgery. Good go to question #3
- 3. How is the heart?
 - LV dysfunction or dilatation Surgery
 - LA dilatation, AF, pulm HTN May consider Surgery
 - "Not" dilated or dysfunctional go to question # 4
- 4. How is the surgeon and what is the most likely operative result?
 - High likelihood of repair AND low operative risk Consider Surgery
 - Otherwise periodic medical surveillance ('watchful waiting')

- 1. How much MR?
 - Not Severe watch. Severe go to question #2
- 2. How is the patient feeling?
 - Bad (dyspnea) Surgery. Good go to question #3
- 3. How is the heart?
 - LV dysfunction or dilatation Surgery
 - LA dilatation, AF, pulm HTN May consider Surgery
 - "Not" dilated or dysfunctional go to question # 4
- 4. How is the surgeon and what is the most likely operative result?
 - High likelihood of repair AND low operative risk Consider Surgery
 - Otherwise periodic medical surveillance ('watchful waiting')
- 5. Is there reasonable expectation of net benefit of surgery?

Is there reasonable expectation of *net* benefit from surgery

- Is there reasonable expectation of benefit?
- Does the expected benefit outweigh the risks?

Is there benefit from surgery?

Asymptomatic patients

- Only benefit is improved life expectancy and event free survival
- Patient must live long enough (several years) to derive tangible benefit from surgery
 - Not elderly
 - No major systemic disease
 - No socioeconomic factors that limit survival

Symptomatic patients

- Expected benefit is improved quality of life (and possibly survival)
 - Reasonable belief that symptoms are due to MR
 - Reasonable expectation that quality of life will improve with MR correction

PRACTICE GUIDELINE

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease




CLASS I

1. Mitral valve surgery is recommended for symptomatic patients with chronic severe primary MR (stage D) and LVEF greater than 30% (365,376). (Level of Evidence: B)

When might the ventricle be too sick for primary mitral valve repair?

- Very depressed ejection fraction (<20%)
- Very remodeled left ventricle (LVEDD > 65 mm)
- Lack of contractile reserve
- Evidence of myocardial scar or fibrosis
- Co-existing severe right ventricular dysfunction

European Guidelines 2012



Is operative risk excessive?

- Chances of achieving long-term benefit are low if upfront risk is high
- If high operative risk, decision for surgery will depend on
 - Symptom severity
 - Patient choice
 - Available alternatives to mitral valve surgery

Is (current) quality of life very limited?

- Will surgery likely improve quality of life?
 - If dominant cause of poor quality of life is cardiac, then worth considering surgery
 - If dominant cause of poor quality of life is non-cardiac then surgery likely futile
 - Severe neurological injury
 - Limited mobility for non-cardiac reasons
 - Severe COPD
 - Severe adverse psychosocial factors

Consider other options

- If benefit uncertain or risks excessive
 - Mitraclip (approved)
 - TMVR (investigational)
- If left ventricular dysfunction is too advanced
 - Transplantation
 - Left Ventricular Assist Device
 - Palliative Care

- 1. How is the valve?
 - Not Severe watch. Severe go to question #2
- 2. How is the patient feeling?
 - Bad (dyspnea) Surgery. Good go to question #3
- 3. How is the heart?
 - LV dysfunction or dilatation Surgery
 - LA dilatation, AF, pulm HTN May consider Surgery
 - "Not" dilated or dysfunctional go to question # 4
- 4. How is the surgeon and what is the most likely operative result?
 - High likelihood of repair AND low operative risk Consider Surgery
 - Otherwise periodic medical surveillance ('watchful waiting')
- 5. Is there reasonable expectation of net benefit of surgery?
 - Yes Mitral surgery. No Medical therapy, percutaneous, other

- 1. How is the Valve?
 - Not Severe watch. Severe go to question #2
- 2. How is the patient feeling?
 - Bad (dyspnea) Surgery. Good go to question #3
- 3. How is the heart?
 - LV dysfunction or dilatation Surgery
 - LA dilatation, AF, pulm HTN May consider Surgery
 - "Not" dilated or dysfunctional go to question # 4
- 4. How is the surgeon and what is the most likely operative result?
 - High likelihood of repair AND low operative risk Consider Surgery
 - Otherwise periodic medical surveillance ('watchful waiting')
- 5. Is there reasonable expectation of net benefit of surgery?
 - Yes Mitral surgery. No Medical therapy, percutaneous, other

